ID

34328

Descripción

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4; ODM derived from: https://clinicaltrials.gov/show/NCT01057667

Link

https://clinicaltrials.gov/show/NCT01057667

Palabras clave

  1. 16/1/19 16/1/19 -
  2. 14/4/19 14/4/19 -
  3. 15/4/19 15/4/19 -
Titular de derechos de autor

see on clinicaltrials.gov

Subido en

16 de enero de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Hepatitis C, Chronic NCT01057667

Eligibility Hepatitis C, Chronic NCT01057667

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
adult patients, 18-70 years of age
Descripción

ID.1

Tipo de datos

boolean

hepatitis c, genotype 1 or 4, of over 6 months duration
Descripción

ID.2

Tipo de datos

boolean

treatment-naïve
Descripción

ID.3

Tipo de datos

boolean

negative pregnancy test; female patients of childbearing age and male patients with female partners of childbearing age must use two forms of contraception during treatment and following the last dose of ribavirin in accordance with locally approved label for ribavirin
Descripción

ID.4

Tipo de datos

boolean

Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
pregnant or breast feeding females or male partners of pregnant females
Descripción

ID.5

Tipo de datos

boolean

previous interferon or ribavirin based therapy or investigational anti-hcv agent
Descripción

ID.6

Tipo de datos

boolean

systemic antiviral therapy with established or perceived activity against hcv </=3 months prior to first dose of study drug
Descripción

ID.7

Tipo de datos

boolean

hepatitis a or b, or hiv infection
Descripción

ID.8

Tipo de datos

boolean

history or evidence of medical condition associated with chronic liver disease other than hcv
Descripción

ID.9

Tipo de datos

boolean

Similar models

Eligibility Hepatitis C, Chronic NCT01057667

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
adult patients, 18-70 years of age
boolean
ID.2
Item
hepatitis c, genotype 1 or 4, of over 6 months duration
boolean
ID.3
Item
treatment-naïve
boolean
ID.4
Item
negative pregnancy test; female patients of childbearing age and male patients with female partners of childbearing age must use two forms of contraception during treatment and following the last dose of ribavirin in accordance with locally approved label for ribavirin
boolean
Item Group
C0680251 (UMLS CUI)
ID.5
Item
pregnant or breast feeding females or male partners of pregnant females
boolean
ID.6
Item
previous interferon or ribavirin based therapy or investigational anti-hcv agent
boolean
ID.7
Item
systemic antiviral therapy with established or perceived activity against hcv </=3 months prior to first dose of study drug
boolean
ID.8
Item
hepatitis a or b, or hiv infection
boolean
ID.9
Item
history or evidence of medical condition associated with chronic liver disease other than hcv
boolean

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial